Summary
Zoetis Inc. (ZTS) reported strong top-line growth for the second quarter and first half of 2024, with total revenue increasing by 8% and 9% respectively, driven by a combination of price increases and volume growth in key product categories like dermatology and new products. Operationally, revenue growth was even more robust, up 11% for the quarter and 12% for the half-year, indicating underlying business strength despite unfavorable foreign exchange impacts. Profitability saw a decline in reported net income for the quarter, primarily due to higher restructuring and divestiture-related costs and other (income)/deductions—net, which included a significant loss on assets held for sale. However, excluding these items, adjusted net income and adjusted diluted EPS showed healthy year-over-year increases, demonstrating continued operational efficiency and profitability.
Financial Highlights
51 data points| Revenue | $2.36B |
| Cost of Revenue | $668.00M |
| Gross Profit | $1.69B |
| SG&A Expenses | $581.00M |
| Interest Expense | $59.00M |
| Net Income | $624.00M |
| EPS (Basic) | $1.37 |
| EPS (Diluted) | $1.37 |
| Shares Outstanding (Basic) | 455.50M |
| Shares Outstanding (Diluted) | 456.00M |
Key Highlights
- 1Total revenue increased by 8% to $2,361 million for the three months ended June 30, 2024, and by 9% to $4,551 million for the six months ended June 30, 2024.
- 2Operational revenue growth, excluding foreign exchange, was strong at 11% for the quarter and 12% for the half-year, driven by price increases and new product volumes.
- 3U.S. segment revenue saw robust growth of 12% for the quarter and 14% for the half-year, primarily driven by companion animal products.
- 4International segment revenue grew 4% for the quarter and 3% for the half-year, with operational growth at 10% and 9% respectively, despite significant foreign exchange headwinds.
- 5The company is actively managing its portfolio, planning to divest its medicated feed additive product portfolio and related assets for $350 million.
- 6Research and development expenses increased by 17% for the quarter and 16% for the half-year, reflecting continued investment in innovation.
- 7Despite a reported decrease in net income attributable to Zoetis Inc. for the quarter, adjusted net income and adjusted diluted EPS increased by 9% and 11% respectively for the quarter, showcasing underlying profitability improvements.